Ucar T-Cell
Multi-Drug Resistant Nephrotic Syndrome
The Children's Hospital of Zhejiang University School of MedicineCell therapyPhase 1Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 89/ 100
Competitive context
2 Active assets in the Multi-Drug Resistant Nephrotic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
RD06-05 CART Cell The Children's Hospital of Zhejiang University School of Medicine | Early Phase 1 | C |
qt-219cx The Children's Hospital of Zhejiang University School of Medicine | Early Phase 1 | C |
Same molecule, other indications
Ucar T-Cell is also rated in:
anti-neutrophil cytoplasmic antibody-associated vasculitisDormant
CCC
Indicative ·
50 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →